Received: 3 June 2020 | Accepted: 15 July 2020

DOI: 10.1111/jth.15022

ORIGINAL ARTICLE

The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience

Raffaele Pesavento[1] | Davide Ceccato[1] | Giampaolo Pasquetto[2] | Jacopo Monticelli[3] | Lucia Leone[4] | Annachiara Frigo[5] | Davide Gorgi[1] | Anna Postal[1] | Giuseppe Maria Marchese[2] | Alberto Cipriani[5] | Alois Saller[1] | Cristiano Sarais[5] | Pietro Criveller[4] | Marco Gemelli[4] | Federico Capone[1] | Paola Fioretto[1] | Claudio Pagano[1] | Marco Rossato[1] | Angelo Avogaro[1] | Paolo Simioni[1] | Paolo Prandoni[6] | Roberto Vettor[1]

[1]Department of Medicine, University of Padua, Padua, Italy

[2]Division of Cardiology, Ospedali Riuniti Padova Sud, Monselice, Italy

[3]Hospital Direction, Ospedali Riuniti Padova Sud, Monselice, Italy

[4]Division of General Medicine, Ospedali Riuniti Padova Sud, Monselice, Italy

[5]Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy

[6]Arianna Foundation on Anticoagulation, Bologna, Italy

Correspondence
Raffaele Pesavento, Clinica Medica 3, Azienda Ospedale-Università di Padova, Padova, Italy.
Email: raffaele@pesavento.eu

Abstract

Background: Coronavirus Disease 2019 (COVID-19) is responsible for a worldwide pandemic, with a high rate of morbidity and mortality. The increasing evidence of an associated relevant prothrombotic coagulopathy has resulted in an increasing use of antithrombotic doses higher than usual in COVID-19 patients. Information on the benefit/risk ratio of this approach is still lacking.

Objective: To assess the incidence of relevant bleeding complications in association with the antithrombotic strategy and its relationship with the amount of drug.

Methods: Consecutive COVID-19 patients admitted between February and April 2020 were included in a retrospective analysis. Major bleedings (MB) and clinically relevant non-major bleeding (CRNMB) were obtained from patient medical records and were adjudicated by an independent committee.

Results: Of the 324 patients who were recruited, 240 had been treated with prophylactic doses and 84 with higher doses of anticoagulants. The rate of the composite endpoint of MB or CRNMB was 6.9 per 100-person/months in patients who had been given prophylactic doses, and 26.4 per 100-person/months in those who had been prescribed higher doses (hazard ratio, 3.89; 95% confidence interval, 1.90-7.97). The corresponding rates for overall mortality were 12.2 and 20.1 per 100-person/months, respectively.

Conclusions: The rate of relevant bleeding events was high in patients treated with (sub)therapeutic doses of anticoagulants. In the latter group, overall mortality did not

R.P. and D.C. are joint co-first authors.

P.P. and R.V. are joint co-senior authors.

Manuscript handled by: Sabine Eichinger

Final decision: Sabine Eichinger, 15 July 2020

differ from that of patients treated with standard prophylactic doses and was even higher. Our result does not support a strategy of giving (sub)therapeutic doses of anticoagulants in non-critically ill patients with COVID-19.

KEYWORDS

anticoagulants, bleeding, coronavirus 2019, COVID-19, venous thromboembolism

1 | INTRODUCTION

Coronavirus Disease 2019 (COVID-19), or acute respiratory disease determined by a novel beta coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an infectious respiratory disease, responsible for a worldwide pandemic, with a high rate of morbidity and mortality.[1-7] COVID-19 is characterized by a wide spectrum of clinical manifestations, ranging from no or flulike syndrome to severe acute respiratory distress syndrome. In current practice, mainly based on the experience gained in China, where the first disease outbreak developed in late 2019, symptomatic patients are treated with pharmacological cocktails including antiviral agents, hydroxychloroquine, macrolides, and antiphlogistic and antithrombotic drugs.[2,8-15]

The use of antithrombotic agents in COVID-19 hospitalized patients was initially guided by the recommendations issued by several international societies for protection against venous thromboembolism (VTE) in high-risk medical patients.[16] Later on, increasing evidence has shown that a remarkable prothrombotic coagulopathy may occur in the clinical course of several COVID-19 patients, leading to the development of fatal and nonfatal venous and arterial complications, even in patients who had been administered prophylactic doses of heparins or fondaparinux.[13,17-28] This has resulted in an increasing use of antithrombotic doses higher than usual, especially in patients perceived as being at a higher thromboembolic risk because of an unusually high D-dimer value and/or the presence of additional comorbidities.[13] Because available information on the benefit/risk profile of this approach is still lacking, we retrieved information from a broad number of consecutive patients with noncritical COVID-19 who had been admitted to two medical wards and had been prescribed variable doses of antithrombotic drugs according to the physicians' perception of the thromboembolic risk. The primary study endpoint was the incidence of relevant bleeding complications occurring in association with the antithrombotic strategy, and its relationship with the amount of drug. We also assessed whether and to what extent factors other than antithrombotic agents can affect the hemorrhagic risk. The choice of the drug was left to the discretion of attending physicians, as was its dosage and duration.

Essentials

- In COVID, information on benefit/risk ratio of (sub)therapeutic doses of anticoagulants is lacking.
- We evaluated the rate of bleeding in non-critically ill COVID patients who received anticoagulants.
- The rate of bleeding was high in patients treated with (sub)therapeutic doses of anticoagulants.
- In the latter, overall mortality did not differ from that of patients treated with prophylactic doses.

2 | METHODS

2.1 | Patients

All consecutive patients admitted to two medical wards (the nonintensive COVID-19 Unit of the University Hospital of Padua and the COVID-19 Hospital of the Padua Province, Ospedali Riuniti Padova Sud, Monselice, both in Northern Italy) with laboratory-confirmed SARS-CoV-2 infection between February 26 and April 6, 2020, were eligible for this retrospective investigation. According to the World Health Organization laboratory guidelines, confirmation for SARS-CoV-2 was defined as a positive result of real-time reverse transcriptase-polymerase chain reaction assay of nasal and pharyngeal swabs.[1] Patients with critical disease (ie, patients requiring intubation for ventilatory support or intensive care) were excluded, as were those who could not receive antithrombotic prophylaxis and those on indefinite treatment with vitamin K antagonists or direct oral anticoagulants for cardiovascular disorders. The investigation was conducted according to the principles expressed in the Declaration of Helsinki (2001) and local regulations. The study protocol was approved by the cardiovascular section in-house Ethics Committee on Human Research of the Padua Province.

2.2 | Data collection

Study data and clinical information were collected and managed by medical staff using REDCap electronic data capture tools hosted at the University of Padua. For each patient, the following baseline data were collected: age, sex, body mass index, D-dimer, history of previous VTE or bleeding, the Padua Prediction Score (PPS), and several bleeding risk factors (indicated in Table 1). In addition, the main pharmacologic treatments other than antithrombotic drugs were recorded, as was the need for subsequent intensive care.

TABLE 1 Baseline and clinical characteristics of patients who had been given prophylaxis and nonprophylaxis doses of anticoagulants[a]

	Prophylactic Dose (N = 240)	(Sub) therapeutic Dose (N = 84)
Age, years; median, (IQR)	70 (57-81)	77 (62-86)
Sex, males	130 (54.2)	51 (60.7)
Obesity (N = 213)	37 (15.4)	12 (14.3)
Previous VTE	10 (4.2)	7 (8.3)
COVID-pneumonia severity at admission		
Need of low-flow oxygen	177 (73.8)	62 (73.8)
Need of reservoir mask	51 (21.3)	18 (21.4)
Need of high-flow oxygen	12 (5.0)	4 (4.8)
In-hospital stay duration, days, median, (IQR)	12 (8-18)	17 (11-30)
Need of subsequent ICU care	7 (2.9)	23 (27.4)
ICU stay duration, days, median, (IQR)	10 (4-12)	12 (7-18)
PPS ≥ 4	103 (42.9)	56 (66.7)
D-dimer, ug/L; median, (IQR) (N = 281)	252 (155-501)	270 (154-759)
Bleeding risk factors		
e-GFR ≥ 60 mL/min/1.73 m^2	183 (76.3)	53 (63.1)
e-GFR 30-59 mL/min/1.73 m^2	44 (18.3)	24 (28.6)
e-GFR < 30 mL/min/1.73 m^2	13 (5.4)	7 (8.3)
Acute liver failure	9 (3.8)	0
Bleeding history	9 (3.8)	1 (1.2)
Uncontrolled hypertension	55 (22.9)	14 (16.7)
Chronic blood diseases	5 (2.1)	3 (3.6)
Alcohol abuse	2 (0.8)	0
Thrombocytopenia (<50 × 10^9/L)	3 (1.3)	1 (1.2)
GI cancer	1 (0.4)	1 (1.2)
Type of anticoagulant administered		
UFH	1 (0.4)	0
LMWH	193 (80.8)	78 (92.9)
Fondaparinux	45 (18.8)	6 (7.1)
Dose of anticoagulant administered		
UFH 5000 U TID	1	0
LMWH 40 mg OD	193	0
LMWH 1 mg/kg BID	0	71
LMWH 0.5 mg/kg BID	0	7
Fondaparinux 2.5 mg	45	0
Fondaparinux 7.5 mg	0	6
Laboratory-adjusted doses	0	0
LMWH daily dose, mg, median (IQR)	-	120 (80-140)
LMWH daily dose, mg, min-max	-	40-200
Type of antiplatelet therapy administered		
None	186 (77.5)	66 (78.6)
SAPT	50 (20.8)	17 (20.2)
DAPT	4 (1.7)	1 (1.2)
COVID-specific treatments		
Ritonavir/lopinavir	42 (17.5)	21 (25.0)
Hydroxychloroquine	180 (75.0)	71 (84.5)
Tocilizumab	6 (2.5)	14 (16.7)
Remdesivir	1 (0.4)	2 (2.4)
Antibiotics	170 (70.8)	57 (67.9)
Steroids	77 (32.1)	27 (32.1)
PPI	154 (64.2)	68 (81.0)

Abbreviations: BID, twice daily; DAPT, dual antiplatelet therapy; e-GFR, estimated glomerular filtration rate (CKD-EPI); GI, gastrointestinal; ICU, intensive care unit; IQR, interquartile range; LMWH, low molecular weight heparin; OD, once daily; PPI, proton-pump inhibitor; PPS, Padua Prediction Score; SAPT, single antiplatelet therapy; UFH, unfractionated heparin.

[a]Values are expressed as number and percentage in round brackets unless otherwise indicated.

2.3 | Study groups

The choice of the antithrombotic agent was left to the discretion of attending physicians, who decided to use prophylactic or higher doses based on the perceived thromboembolic risk, in turn guided by the value of baseline D-dimer and/or the presence of comorbidities, such as obesity, cancer, venous insufficiency, personal or familiar history of VTE, known thrombophilia, or ongoing treatment with hormonal or antipsychotic drugs. From the clinical charts, we retrieved information on each of the three antithrombotic drugs that had been administered (unfractionated heparin, enoxaparin, or fondaparinux), and predefined the dose intensity as being prophylactic or higher. Daily doses of unfractionated heparin up to 15 000 U, of enoxaparin up to 4000 U and of fondaparinux up to 2.5 mg were labeled as prophylactic (prophylaxis group). Higher daily doses, usually adjusted to body weight or laboratory parameters, were aggregated in one group, the (sub)therapeutic group, regardless of the drug amount.

2.4 | Study outcomes

The primary endpoint was the composite of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) occurring in each

of the two study groups during the administration of antithrombotic agents (up to 2 days after their discontinuation). Secondary outcomes were the single components of the primary one, as were objectively confirmed symptomatic VTE and all-cause mortality. The severity of bleeding was defined according to the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.[29] An independent committee, unaware of the patients' clinical details, reviewed and adjudicated all bleeding events. For the confirmation of lower extremities deep vein thrombosis and pulmonary embolism, leg vein ultrasonography and computed tomography angiography were used, respectively, with the adoption of widely accepted diagnostic criteria.

2.5 | Statistical analysis

The time to the primary outcome of MB or CRNMB was calculated as the time from hospitalization to the event occurred or to death or VTE for those patients who experienced these events during the 30 days of hospitalization or 30 days for the survivors. Death and VTE were considered competing events. The rate of the primary composite outcome was estimated with 95% confidence intervals (CI) calculated with the Poisson method. Potential predictors of the primary outcome were tested in a univariate Cox regression model for competing hazards using the Fine and Gray method and those found to be statistically significant at the 10% level were included in a multivariable Cox regression model with stepwise backward selection. Potential predictors of death for any cause were tested in a univariate Cox regression model, and those found to be statistically significant at the 10% level were included in a multivariable Cox regression model with stepwise backward selection. Results are presented as *P* values and hazard ratios (HR) with 95% CIs. All the statistical tests were two-tailed and conducted at a significance level of 5% if not otherwise stated and the analyses were performed with SAS 9.4 (SAS Institute Inc, Cary, NC) for Windows.

3 | RESULTS

3.1 | Patients and study groups

Overall, we retrieved data from 448 eligible patients with non-critically ill COVID-19. Of them, 23 were excluded because of the need for intensive care or ventilatory support at the time of admission, 53 because of indefinite treatment with vitamin K antagonists or novel anticoagulants, and 48 because of lack of antithrombotic prophylaxis. Accordingly, 324 patients were recruited for the current investigation. The median age was 71 years (interquartile ratio [IQR], 59-82) years and 181 were men (55.9%). In all patients, radiologic and thoracic ultrasound findings of COVID-19 were found.

Of the 324 patients, 240 had been treated with prophylactic doses of anticoagulants (1 with unfractionated heparin, 193 with low molecular weight heparin [LMWH] and 45 with fondaparinux); and the remaining 84 with higher doses (sub)therapeutic doses (78 with LMWH and 6 with fondaparinux). More details about higher doses are displayed in Table 1.

At variable time during hospitalization, 30 patients (9.3%) required intensive care for a median length of stay in intensive care unit of 11 days (IQR, 6-17): 7 (2.9%) in the prophylaxis group and the remaining 23 (27.4%) in the treatment group.

Table 1 summarizes the main baseline and clinical characteristics of the study cohort separately for each group.

3.2 | Study outcomes

Table 2 details the primary and secondary events occurring in our cohort separately in each of the two study groups. During anticoagulation, the primary endpoint developed in 15 patients who had been given prophylactic doses (11 receiving LMWH and 4 fondaparinux), corresponding to an incidence rate of 6.9 per 100-person/months (95% CI, 3.9-11.5; 8 MB and 7 CRNMB), and in 18 patients who had been prescribed (sub)therapeutic doses (LMWH and fondaparinux in 17 and one, respectively), corresponding to an incidence rate of 26.4

TABLE 2 Incidence rate of the outcomes

	Prophylactic Dose (N = 240)		(Sub)therapeutic Dose (N = 84)	
	N	Rate[b]	N	Rate[b]
Primary endpoint[a]	15	6.9 (3.9-11.5)	18	26.4 (15.6-41.7)
MB	8	3.7 (1.6-7.3)	8	11.7 (5.1-23.1)
CRNMB	7	3.2 (1.3-6.7)	10	14.6 (7.0-26.9)
Fatal bleeding	2	0.9 (0.1-3.3)	2	2.9 (0.3-10.6)
VTE	6	2.8 (1.0-6.0)	3	4.4 (0.9-12.8)
Death for any cause	27	12.2 (8.1-17.8)	14	20.1(11.0-33.8)
Type of MB event				
Intracranial	1	-	0	-
Retroperitoneal	3	-	3	-
Gastrointestinal	3	-	3	-
Intrauterine	1	-	0	-
Muscles	0	-	2	-
Type of VTE event				
Pulmonary embolism	1	-	0	-
DVT in lower limbs	2	-	2	-
DVT in other sites	3	-	1	-

Abbreviations: CRNMB, clinically relevant non-major bleeding; DVT, deep vein thrombosis; MB, major bleeding; VTE, venous thromboembolism.

[a]MB and/or CRNMB; [b]Per 100-person/months (95% confidence interval).

per 100-person/months (95% CI, 15.6-41.6; 8 MB and 10 CRNMB). Two fatal bleeding events developed in patients who had received prophylactic doses (0.9 per 100-person/months) and two in patients who had been prescribed higher doses (2.9 per 100-person/months).

VTE developed in six patients who had been given prophylactic doses and in three patients who had been prescribed higher doses. Death from any cause was reported in 27 patients who had been given prophylactic doses, corresponding to an incidence rate of 12.2 per 100 person/months (95% CI, 8.1-17.8) and in 14 patients who had been prescribed higher doses, corresponding to an incidence rate of 20.1 per 100 person/months (95% CI, 11.0-33.8). Age > 80 years, high PPS, COVID phenotype, and moderate-to-severe renal impairment were found to be independent predictors of all-cause mortality (Table 3).

3.3 | Predictors of the primary endpoint

In the multivariable Cox regression model, use of (sub)therapeutic doses of anticoagulants (HR 3.89; 95% CI, 1.90-7.97; $P < .001$), age older than 80 years (HR, 3.40; 95% CI, 1.51-7.65; $P = .003$) and concomitant dual antiplatelet therapy (HR, 9.4; 95% CI 2.6-33.7; $P < .001$) were found to be independent predictors of major or clinically relevant non-major bleeding (Table 4).

TABLE 3 Characteristics of the study patients by mortality and results of the multivariate Cox regression analysis

	Death for Any Cause		
	HR	95% CI	P
PPS ≥ 4	2.59	1.16-5.78	.02
Age > 80 y	2.87	1.36-6.03	.005
COVID phenotype 2	2.78	1.48-5.23	.001
eGFR 30-59 mL/min/1.73 m^2	3.01	1.40-6.48	.005
eGFR < 30 mL/min/1.73 m^2	6.61	2.77-15.74	<.001

Note: Age, gender, PPS, eGFR, COVID phenotype, antiplatelet, antibiotic, steroid, and proton-pump inhibitors treatment were included in the multivariate regression model.

Abbreviations: eGFR, estimated glomerular filtration rate; PPS, Padua Prediction Score.

TABLE 4 Characteristics of the study patients by bleeding complications and results of the multivariate Cox regression analysis for competitive risks

	Primary Endpoint[a]		
	HR	95% CI	P
AC (sub)therapeutic doses	3.89	1.90-7.97	<.001
Age > 80 y	3.40	1.51-7.65	.003
SAPT	0.68	0.24-1.93	.47
DAPT	9.4	2.6-33.7	<.001

Abbreviations: AC, anticoagulants; CRNMB, clinically relevant non-major bleeding; DAPT, dual drug antiplatelet therapy; eGFR, estimated glomerular filtration rate; MB, major bleeding; SAPT, single drug antiplatelet therapy.

[a]MB and/or CRNMB; age, eGFR < 30 mL/min/1.73 m^2, eGFR 30-59 mL/min/1.73 m^2, eGFR ≥ 60 mL/min/1.73 m^2, 2 D-dimer, history of VTE, and concomitant antiplatelet therapy were included in the multivariate regression model.

4 | DISCUSSION

The increasing awareness that low-dose anticoagulants may be ineffective for prevention of thrombotic complications in the course of COVID-19, including the development of microthrombosis in the lung vessels, has induced several clinicians to consider the use of (sub) therapeutic or even therapeutic doses of antithrombotic agents in all admitted patients, challenging their hemorrhagic potential.[13,30] The results of our retrospective cohort study do not support this strategy. Indeed, the rate of symptomatic complications occurring during the clinical course of patients who received (sub)therapeutic doses of heparins or fondaparinux did not differ from that of patients given conventional preventive doses, nor did the rate of overall mortality, which was even higher in the former group, most likely because of the recruitment of patients who were on average older and had a higher thromboembolic risk. By converse, the rate of clinically relevant bleeding complications among patients allocated to (sub)therapeutic doses exceeded by far that recorded among those treated with preventive doses. Based on the results of our multivariate proportional hazards regression model, the anticoagulant dose was the strongest determinant of the bleeding risk. Because the benefit/risk ratio of high-dose anticoagulants is in striking contrast with that expected in the treatment of most patients with acute vascular disorders,[31] our results suggest that thrombotic complications are unlikely to play a key role in determining the prognosis of COVID-19.

Although obtained with a retrospective study, our results are robust. We recruited two large cohorts of consecutive patients who were admitted to medical wards. In addition, predefined criteria were used for the adjudication of the primary endpoint. Finally, because of the general difficulty in interpreting the cause of death we decided to include all-cause mortality among the (secondary) endpoints, in such a way accepting the risk of diluting the contributing role of PE to the patients' mortality but obviating that of missing deaths imputable to pulmonary embolism or thrombosis.

Not surprisingly, the incidence of major or clinically relevant bleeding complications occurring during hospitalization was remarkably higher in patients treated with (sub)therapeutic than in those receiving preventive doses of antithrombotic drugs. Of interest, in each of the two study cohorts, the observed incidence was consistent with that expected in the respective field.[16,31] Because (sub) therapeutic doses of antithrombotic drugs failed to reduce the risk of fatal or nonfatal thrombotic complications while simultaneously increasing the hemorrhagic risk, their use in patients with non-critically ill COVID-19 should be discouraged. Our results are consistent with those of a recent multicenter retrospective American study.[33]

Among the potential study limitations are the lack of a standardized approach for the detection of VTE disorders and the

heterogeneous distribution of baseline parameters between the two study groups.

Unusually crowded wards and inherent risks of contagion dissemination led attending physicians to modify the diagnostic workup for suspected VTE, limiting the ultrasound detection of deep vein thrombosis only to patients with unexplained leg edema and computed tomography pulmonary angiography only to those with inexplicable worsening of their respiratory symptoms.

This can account for the discrepancy between our findings and those of recent studies where the occurrence of VTE complications was instead more extensively investigated.[20,32] In our study cohort, both patients treated with prophylactic and those treated with higher dose of anticoagulants had low median plasma levels of D-dimer (255 and 270 μg/L, respectively). Levels higher than 1000 μg/L were found in only 11% of cases. Of interest, in these patients, the risk of bleeding, VTE, and death was not influenced by the anticoagulant dose (data not reported). According to the results of Tang et al[13] on patients with severe COVID-19, prophylactic doses of heparin reduced mortality compared with no treatment only in patients with D-dimer levels higher than 3000 μg/L, whereas no effect was observed in those with lower levels. Therefore, use of (sub)therapeutic doses in patients with less severe COVID-19 and lower D-dimer levels is unlikely to be beneficial while increasing the bleeding risk.

The discrepancy in the baseline laboratory and clinical parameters between the two groups is, in turn, dependent on the arbitrary selection of anticoagulant doses. In fact, the decision was left to attending physicians, who generally prescribed the (sub)therapeutic doses to patients perceived as being at a higher thromboembolic risk. Not surprisingly, therefore (as shown in Table 1), patients belonging to the latter group were on average older, had a higher PPS and a longer hospital stay, and more often needed intensive care. Because of these unavoidable limitations, we decided not to include the rate of VTE complications and that of death among the primary study endpoints. By contrast, the primary safety outcomes (MB and CRNMB) were accurately recorded and classified and were independently reviewed. As a result of our multivariate proportional hazards regression model, the dose of antithrombotic agents was the main contributor to the remarkable excess in the bleeding risk observed among patients receiving high doses of the antithrombotic drug over those assigned low preventive doses.

Of interest, among the five patients treated with concomitant dual antiplatelet therapy, two developed a clinically relevant bleeding (one major bleeding in a patient treated with enoxaparin prophylactic dose and one CRNMB in a patient treated with weight-adjusted dose). Not surprisingly, the administration of dual or triple antithrombotic therapies can significantly increase the risk of bleeding in patients with COVID-19.

In conclusion, the results of our study do not support the currently adopted strategy of giving weight-adjusted doses of anticoagulants in non-critically ill patients with COVID-19 in the absence of thromboembolic complications. They are likely to be dangerous and ineffective. We acknowledge that because of the retrospective design of our study and of its limitations, our results may not be strong enough to allow definitive conclusions. Furthermore, as for the current investigation we recruited only noncritically ill patients, our conclusions may not apply to more severe patients. The results of prospective randomized studies, including severe patients, are warranted.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHOR CONTRIBUTIONS

Study concept and design: Raffaele Pesavento and Davide Ceccato. Acquisition, analysis, or interpretation of data: Davide Ceccato, Davide Gorgi, Anna Postal, Giuseppe M. Marchese, Alberto Cipriani, Pietro Criveller, Marco Rossato, Marco Gemelli, Federico Capone, Paola Fioretto, and Angelo Avogaro. Drafting of the manuscript: Raffaele Pesavento, Paolo Prandoni, Davide Ceccato, Angelo Avogaro, and Roberto Vettor. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: Annachiara Frigo, Raffaele Pesavento. Administrative, technical, or material support: Raffaele Pesavento and Paolo Prandoni. Study supervision: Raffaele Pesavento, Giampaolo Pasquetto, Davide Ceccato, and Giuseppe M. Marchese. Raffaele Pesavento had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

ORCID

Raffaele Pesavento https://orcid.org/0000-0001-9578-3455
Marco Gemelli https://orcid.org/0000-0003-2902-7947

REFERENCES

1. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance, 25 January 2020. Published January 25, 2020. Accessed March 30, 2020. https://apps.who.int/iris/handle/10665/330854
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382:727-733.
3. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern [published correction appears in Lancet. 2020 Jan 29]. *Lancet*. 2020;395:470-473.
4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395:507-513.
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30]. *Lancet*. 2020;395:497-506.
6. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. *JAMA*. 2020;323:1061-1069.
7. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [published correction appears in Lancet Respir Med. 2020 Apr; 8:e26]. *Lancet Respir Med*. 2020;8:475-481.
8. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med*. 2020;7(382):1787-1799.

9. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*. 2020;395:1569-1578.
10. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20]. *Int J Antimicrob Agents*. 2020;56:105949.
11. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob Agents*. 2020;55:105938.
12. Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: a single center experience. *J Med Virol*. 2020;92:814–818.
13. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*. 2020;18:1094-1099.
14. Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. *J Thromb Haemost*. 2020;18:1752–1755.
15. Casini A, Alberio L, Angelillo-Scherrer A, et al. Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis. *Swiss Med Wkly* 2020;150:w20247.
16. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141(2 Suppl):e195S-e226S.
17. Chen C, Zhang XR, Ju ZY, et al. Advances in the research of cytokine storm mechanism induced by Coronavirus disease 2019 and the corresponding immunotherapies. *Zhonghua Shao Shang Za Zhi*. 2020;36:E005.
18. Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. *Circulation*. 2020;142:184–186.
19. Connors JM, Lewy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood*. 2020;135:2033–2040.
20. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;S0049-3848(20):30120-30121.
21. Danzi GB, Loffi M, Galeazzi G, et al. Acute pulmonary embolism and COVID-19 pneumonia: a random association? *Eur Heart J*. 2020;14(41):1858.
22. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. *Thromb Haemost*. 2020;120::998–1000.
23. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. *J Am Coll Cardiol*. 2020; S0735-1097(20):35008-35017.
24. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. *N Engl J Med*. 2020;382:e38.
25. Yin S, Huang M, Li D, et al. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. *J Thromb Thrombolysis*. 2020; 1-4.
26. Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. *Am J Respir Crit Care Med*. 2020;201:1372–1379.
27. Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. *Lancet Haematol*. 2020;7:e362-e363.
28. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan. *Italy Thromb Res*. 2020;191:9–14.
29. Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *J Thromb Haemost*. 2015;13:2119-2126.
30. Khan IH, Savarimuthu S, Tsun Leung MS, Harky A. The need to manage the risk of thromboembolism in COVID-19 patients [published online ahead of print, 2020 May 14]. *J Vasc Surg*. 2020;S0741-5214(20):31157-31165.
31. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [published correction appears in Chest. 2016 Oct; 150:988]. *Chest*. 2016;149:315-352.
32. Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis [published online ahead of print, 2020 Apr 30]. *Thromb Res*. 2020;S0049-3848(20):30157-30162.
33. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection. *Blood*. 2020;136: 489–500.

How to cite this article: Pesavento R, Ceccato D, Pasquetto G, et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. *J Thromb Haemost*. 2020;18:2629–2635. https://doi.org/10.1111/jth.15022